Lilly to acquire Morphic to improve outcomes for patients with inflammatory bowel disease

Acquisition to expand Lilly's immunology pipeline with oral integrin therapies

Olverembatinib approved for commercialization in Macau China

Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program

Biogen completes acquisition of HI-Bio

Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study

Merck inks MoU with Afrigen Biologics for development of mRNA vaccine technology platform

Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization

Sipavibart EMA regulatory submission accepted under accelerated assessment for COVID-19 prevention

Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population

Orchid Pharma and Cipla collaborate to launch antibiotic Cefepime-Enmetazobactam in India

The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR

Zydus and Dr. Reddy's announce licensing agreement for co?marketing of Pertuzumab biosimilar

Ascentage Pharma closes US$ 75 million equity investment by Takeda

Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO

Truqap plus Faslodex approved in the EU for patients with advanced ER-positive breast cancer

Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population

Bristol Myers Squibb receives USFDA accelerated approval of Krazati in combination with Cetuximab for CRC

Second FDA approval for KRAZATI - reinforcing its potential across tumor types